Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
39.86
+0.14 (0.35%)
NASDAQ · Last Trade: Apr 1st, 6:40 PM EDT
Detailed Quote
Previous Close
39.72
Open
39.75
Bid
39.25
Ask
40.25
Day's Range
39.52 - 39.99
52 Week Range
9.600 - 40.26
Volume
11,441,469
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,582,657
Chart
About Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Centessa Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative medicines to address unmet medical needs. The company's unique asset-centric approach leverages a diverse portfolio of drug candidates, targeting various diseases and conditions, particularly in areas such as oncology, immunology, and rare diseases. Centessa collaborates with leading scientific experts and employs advanced technologies to advance its therapeutic programs through clinical trials, aiming to bring transformative treatments to patients worldwide. Read More
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq: CNTA) in a blockbuster transaction valued at up to $7.8 billion. This acquisition marks a watershed moment for the treatment of sleep-wake disorders and underscores the intense [...]
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY). Once a steady mid-tier giant known for insulin and antidepressants, Lilly has transformed into the world’s first trillion-dollar healthcare titan. Today’s announcement—a definitive $6.3 [...]
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Centessa Pharmaceuticals plc (NASDAQ: CNTA) to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones.
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.
